|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,994,364: Crizotinib Salts and Polymorphs
U.S. Patent 7,994,364, titled "CRIZOTINIB SALTS AND POLYMORPHS," was granted on August 9, 2011, to Pfizer Inc. The patent claims specific crystalline forms and salts of crizotinib, the active pharmaceutical ingredient in Xalkori, an anaplastic lymphoma kinase (ALK) inhibitor used to treat certain types of non-small cell lung cancer. The patent's scope and claims directly impact the commercialization and market exclusivity of crizotinib-based therapies.
What are the core claims of U.S. Patent 7,994,364?
The patent's primary claims revolve around the identification, characterization, and potential use of specific crystalline forms (polymorphs) and salt forms of crizotinib. These forms are asserted to possess advantageous properties, such as improved solubility, stability, and bioavailability, which are critical for pharmaceutical development and efficacy.
- Claim 1: This independent claim defines a specific crystalline form of crizotinib, designated as Form I, characterized by its X-ray powder diffraction (XRPD) pattern. The claim specifies particular peak positions and relative intensities as defining features of this crystalline form.
- Claim 2: This claim defines a second crystalline form of crizotinib, designated as Form II, also characterized by its XRPD pattern, detailing its unique peak positions and intensities.
- Claim 3: This claim defines a third crystalline form of crizotinib, designated as Form III, characterized by its XRPD pattern, including specific peak data.
- Claim 4: This claim defines a fourth crystalline form of crizotinib, designated as Form IV, identified by its distinct XRPD profile.
- Claim 5: This claim covers a crystalline form of crizotinib hydrochloride, designated as Form A, characterized by its XRPD pattern and further described by differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) data.
- Claim 6: This claim defines a crystalline form of crizotinib hydrochloride, designated as Form B, characterized by its XRPD pattern and DSC/TGA data.
- Claim 7: This claim asserts a method of treating a patient afflicted with ALK-positive cancer comprising administering a therapeutically effective amount of a crizotinib salt or polymorph as defined in any one of claims 1 to 6.
- Dependent Claims: The patent includes numerous dependent claims that further refine the scope of the crystalline forms and salts, often referencing or adding specific characteristics or limitations to the independent claims. These can include specific ranges of XRPD peaks, DSC thermal events, or TGA weight loss.
What is the significance of polymorphs and salt forms in drug patents?
Polymorphs are different crystalline structures of the same chemical compound. Salt forms are created when a basic drug molecule reacts with an acid, or an acidic drug molecule reacts with a base. Both polymorphs and salt forms can significantly influence a drug's physical and chemical properties, including:
- Solubility: Affects how quickly and to what extent the drug dissolves in bodily fluids, impacting absorption and bioavailability.
- Stability: Influences the drug's shelf life and its resistance to degradation under various environmental conditions (heat, humidity, light).
- Bioavailability: The fraction of an administered dose that reaches systemic circulation and is available to produce an effect.
- Manufacturability: Certain forms can be easier to process, formulate into dosage forms (tablets, capsules), and manufacture at scale.
Patenting specific polymorphs and salt forms provides an additional layer of intellectual property protection beyond the patent covering the active pharmaceutical ingredient (API) itself. This is crucial because different polymorphs or salt forms can be considered distinct inventions if they exhibit novel and non-obvious properties that offer a therapeutic or manufacturing advantage. This strategy can extend market exclusivity and prevent generic competitors from marketing their versions of the drug using alternative, but equally effective, crystalline or salt forms.
What is the prosecution history of U.S. Patent 7,994,364?
The prosecution history provides insight into the examination process by the U.S. Patent and Trademark Office (USPTO) and the arguments made by the applicant.
- Filing Date: The application that led to U.S. Patent 7,994,364 was filed on August 29, 2007, as U.S. Patent Application No. 11/844,834.
- Issuance Date: The patent was granted on August 9, 2011.
- Key Examination Stages: During prosecution, the examiner reviews the claims against prior art (existing patents and publications). The applicant must demonstrate that their invention is novel, non-obvious, and adequately described. This often involves responding to rejections based on prior art by amending claims or providing arguments and evidence to distinguish the claimed invention.
- Focus of Examination: For U.S. Patent 7,994,364, the examination likely focused on differentiating the claimed crystalline forms and salts of crizotinib from any known forms or related compounds. Evidence of improved properties (e.g., solubility, stability) would have been critical for overcoming prior art rejections, particularly under 35 U.S.C. § 103 (obviousness).
What is the relationship between U.S. Patent 7,994,364 and the original crizotinib composition of matter patent?
U.S. Patent 7,994,364 is a "polymorph patent" or "salt patent," which is typically filed after the initial "composition of matter" patent for the active pharmaceutical ingredient (API) crizotinib.
- Composition of Matter Patent: This patent claims the chemical structure of crizotinib itself. It provides the foundational patent protection for the molecule. This patent is typically filed early in the drug discovery process.
- Polymorph/Salt Patents: These patents claim specific solid-state forms of the API. They are filed later, often when a particular stable, bioavailable, or manufacturable form is identified and developed for clinical use.
U.S. Patent 7,994,364 does not claim the crizotinib molecule itself but rather specific crystalline manifestations and hydrochloride salts thereof. This means that even after the expiration of the primary composition of matter patent for crizotinib, Pfizer could maintain market exclusivity for its Xalkori product as long as U.S. Patent 7,994,364 (and any other relevant secondary patents) remained in force, provided that the marketed form of crizotinib was covered by this patent. The duration of these secondary patents is crucial for understanding the full extent of market exclusivity.
What is the commercial impact and patent landscape surrounding U.S. Patent 7,994,364?
The commercial impact of U.S. Patent 7,994,364 is directly linked to the success of Xalkori (crizotinib) in treating ALK-positive non-small cell lung cancer. The patent provides exclusivity for specific forms of crizotinib, potentially delaying or challenging the market entry of generic versions using these specific forms.
Key aspects of the patent landscape:
- Lanes for Generic Entry: Generic manufacturers must navigate existing patents. If they wish to market a crizotinib product, they must ensure their product does not infringe any valid and in-force patents. This includes the composition of matter patent and any secondary patents like 7,994,364, claiming specific polymorphs or salts.
- "Evergreening" Strategy: The filing of patents for polymorphs, salts, and new formulations is a common strategy in the pharmaceutical industry to extend market exclusivity beyond the term of the original composition of matter patent. This practice, sometimes referred to as "evergreening," can be a point of contention in patent law.
- Litigation: Patents like 7,994,364 are often subject to litigation. Generic companies may challenge the validity of these patents (e.g., arguing they are anticipated by prior art or obvious) or argue that their own product does not infringe the claims. Pfizer, in turn, would defend its patent rights.
- Orange Book Listing: Patents relevant to approved drug products are often listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. This provides notice to generic manufacturers about the patent protection associated with a branded drug. The listing of U.S. Patent 7,994,364 in the Orange Book would signify its importance to the market exclusivity of Xalkori.
- Exclusivity Period: U.S. Patent 7,994,364 has a term that extends 20 years from its filing date, subject to potential patent term extensions due to USPTO delays or regulatory review periods (e.g., under the Hatch-Waxman Act). The effective expiration date of this patent is a critical factor for generic manufacturers planning market entry.
How does the scope of the claims affect potential generic competition?
The specific crystalline forms and salts claimed in U.S. Patent 7,994,364 dictate the types of crizotinib products that would infringe this patent.
- Narrow vs. Broad Claims: If the claimed forms are very specific (e.g., a single, narrow XRPD peak range), generic manufacturers might be able to develop and market a crizotinib product using a different, non-infringing crystalline form or salt. Conversely, broader claims encompassing a wider range of polymorphs or salts would offer stronger protection.
- Characterization Data: The patent's reliance on detailed analytical data (XRPD, DSC, TGA) means that infringement analysis would involve comparing the analytical profiles of a generic product against the claimed characteristics.
- Formulation Considerations: Generic developers must not only develop an API that does not infringe but also a final drug product that avoids infringing any other valid patents, including those covering specific formulations or dosage forms if applicable.
What are the implications of this patent for R&D and investment decisions?
For pharmaceutical companies engaged in R&D or investment in oncology, particularly in ALK-inhibitor space:
- Freedom-to-Operate (FTO) Analysis: Companies developing or investing in crizotinib or similar ALK inhibitors must conduct thorough FTO analyses to ensure their activities do not infringe on existing patents, including 7,994,364.
- Target Identification: Understanding the patent landscape for existing blockbuster drugs like Xalkori helps identify unmet needs and areas where new therapeutic approaches or improved drug forms might be patentable and commercially viable.
- Generic Market Entry Timing: Investors seeking to capitalize on the generic market for crizotinib must carefully track the expiration dates of all relevant patents, including 7,994,364, and the outcomes of any patent litigation.
- Second-Generation Therapies: The existence of patents on specific forms of existing drugs can incentivize the development of next-generation therapies with novel mechanisms of action or significantly improved efficacy and safety profiles, which would then be eligible for their own patent protection.
Key Takeaways
- U.S. Patent 7,994,364 protects specific crystalline forms (Polymorphs I, II, III, IV) and hydrochloride salt forms (Forms A, B) of crizotinib.
- These patented forms are claimed to possess advantageous pharmaceutical properties.
- The patent provides a layer of market exclusivity beyond the original composition of matter patent for crizotinib, impacting generic competition.
- The scope of the claims, defined by specific analytical characteristics, dictates which crystalline or salt forms are protected.
- Understanding this patent is critical for freedom-to-operate analyses and strategic R&D and investment decisions in the oncology sector.
FAQs
- Does U.S. Patent 7,994,364 claim the crizotinib molecule itself?
No, it claims specific crystalline forms and salts of crizotinib, not the chemical structure of crizotinib in general.
- When was U.S. Patent 7,994,364 filed?
The application that led to this patent was filed on August 29, 2007.
- What is the primary drug associated with U.S. Patent 7,994,364?
The drug is Xalkori (crizotinib), used to treat certain types of non-small cell lung cancer.
- Can generic versions of crizotinib be sold before U.S. Patent 7,994,364 expires?
Generic versions can be sold if they do not infringe on any valid and in-force patents, including U.S. Patent 7,994,364, and if other regulatory requirements are met.
- What type of analytical data is used to define the claims in this patent?
The patent claims are defined by characteristics such as X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) thermal events, and thermogravimetric analysis (TGA) weight loss.
Citations
[1] United States Patent 7,994,364. (2011). Crizotinib salts and polymorphs. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
